Management of Pemphigus in COVID-19 Pandemic Era; a Review Article
Archives of Academic Emergency Medicine,
Vol. 8 No. 1 (2020),
7 January 2020
Introduction: The novel coronavirus is rapidly spreading around the world. Since the public announcement of the COVID-19 outbreak, several concerns have been raised by dermatologists as well as pemphigus patients who take immunosuppressive drugs. In this paper, we review the literature about the common treatment of pemphigus with a focus on the lessons from similar epidemics to find a proper suggestion to manage pemphigus in the COVID-19 pandemic era. The effect of many of the drugs used for treatment of Pemphigus vulgaris (PV) on COVID-19 is not clear. We also do not have data on the impact of this autoimmune disease, which may involve the mucous membranes, on the acquisition or course of COVID-19. We are currently in the midst of a pandemic and evaluating the effect of COVID-19 on the population of susceptible patients suffering from auto-immune diseases like pemphigus is essential. The evidence on best ways to manage patients with underlying conditions, such as pemphigus, during the outbreak of COVID-19 is evolving and the data is updated every day.
- severe acute respiratory syndrome coronavirus 2
How to Cite
Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278-80.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020.
Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. New England Journal of Medicine. 2006;355(17):1800-10.
Wu H, Wang ZH, Yan A, Lyle S, Fakharzadeh S, Wahl JK, et al. Protection against pemphigus foliaceus by desmoglein 3 in neonates. New England Journal of Medicine. 2000;343(1):31-5.
Kridin K, Zelber-Sagi S, Bergman R. Pemphigus vulgaris and pemphigus foliaceus: differences in epidemiology and mortality. Acta dermato-venereologica. 2017;97(8-9):1095-9.
Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020:105948.
Zhao CY, Murrell DF. Pemphigus vulgaris: an evidence-based treatment update. Drugs. 2015;75(3):271-84.
Gheisari M, Faraji Z, Dadras MS, Nasiri S, Robati RM, Moravvej H, et al. Methylprednisolone pulse therapy plus adjuvant therapy for pemphigus vulgaris: an analysis of 10 years' experience on 312 patients. Dermatol Ther. 2019;32(5):e13057.
Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. The Lancet infectious diseases. 2009;9(8):493-504.
Pishgahi M, Dadkhahfar S, Robati RM, Kheradmand Z, Shahidi-Dadras M, Zargari O, et al. Electrocardiographic changes after high-dose corticosteroid pulse therapy in pemphigus patients. Journal of Dermatological Treatment. 2018:1-4.
Shahidi-Dadras M, Pishgahi M, Tabary M, Kheradmand Z, Araghi F, Dadkhahfar S, et al. Cardiac function in pemphigus vulgaris patients before and after steroid pulse therapy. J Dermatolog Treat. 2020:1-5.
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020;395(10223):473-5.
Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS medicine. 2006;3(9).
Guo L, Han Y, Li J, Chen Q, Ren Y, Wu Q, et al. Long-term outcomes in patients with severe acute respiratory syndrome treated with oseltamivir: a 12-year longitudinal study. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE. 2019;12(10):12464-71.
Ni Y-N, Chen G, Sun J, Liang B-M, Liang Z-A. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Critical Care. 2019;23(1):99.
Sinha P, Chatterjee M, Vasudevan B. Pemphigus vulgaris: A dermatological sequel of severe H1N1 infection. Indian dermatology online journal. 2014;5(2):216.
Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and Future Therapeutic Strategies. Frontiers in Immunology. 2019;10(1418).
Murrell DF, PeÃ±a S, Joly P, Marinovic B, Hashimoto T, Diaz LA, et al. Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. Journal of the American Academy of Dermatology. 2018.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. The Lancet. 2017;389(10083):2031-40.
Cho A, Bradley B, Kauffman R, Priyamvada L, Kovalenkov Y, Feldman R, et al. Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab. JCI insight. 2017;2(12).
Kasperkiewicz M, Eming R, Behzad M, Hunzelmann N, Meurer M, Schulzeâ€Koops H, et al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2012;10(10):727-31.
Chiu H-Y, Chang C-Y, Hsiao C-H, Wang L-F. Concurrent cytomegalovirus and herpes simplex virus infection in pemphigus vulgaris treated with rituximab and prednisolone. Acta dermato-venereologica. 2013;93(2):200-1.
Wei K, Wang Y, Wang W, Chen W. Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab. Journal of the European Academy of Dermatology and Venereology. 2017;31(8):e350-e1.
Atkinson JR, Bergmann CC. Protective humoral immunity in the central nervous system requires peripheral CD19-dependent germinal center formation following coronavirus encephalomyelitis. Journal of virology. 2017;91(23):e01352-17.
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Hostâ€“Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chemical Neuroscience. 2020.
Murrell DF, Pena S, Joly P, Marinovic B, Hashimoto T, Diaz LA, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575-85 e1.
Atzmony L, Hodak E, Leshem YA, Rosenbaum O, Gdalevich M, Anhalt GJ, et al. The role of adjuvant therapy in pemphigus: a systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2015;73(2):264-71.
Kim S-H, Ko J-H, Park GE, Cho SY, Ha YE, Kang J-M, et al. Atypical presentations of MERS-CoV infection in immunocompromised hosts. Journal of infection and chemotherapy. 2017;23(11):769-73.
Brown AE, Motaparthi K, Hsu S. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients. Dermatol Online J. 2018;23(12).
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. Journal of Medical Virology. 2020;92(5):479-90.
Lew TW, Kwek T-K, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. Jama. 2003;290(3):374-80.
Pathoulas JT, Stoff BK, Lee KC, Farah RS. Ethical Outpatient Dermatology Care During the Coronavirus (COVID-19) Pandemic. Journal of the American Academy of Dermatology.
Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? International Journal of Antimicrobial Agents. 2020:105938.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet.
- Abstract Viewed: 324 times
- PDF Downloaded: 271 times
- HTML Downloaded: 12 times